15. Expansion Plan
Strategic roadmap for geographic, segment, and model growth post-US PMF. Prioritizes low-risk English markets and B2B adjacencies in healthcare.
Pending1. Expansion Readiness Assessment
Expansion gated on US PMF. Recommended timing: Months 7-9 after D30 retention >40% and LTV:CAC >3:1.
| Criterion | Status | Target | Notes |
|---|---|---|---|
| Product-Market Fit (US) | 🟡 Pending | D30 retention >40% | Validate matching accuracy & notifications |
| Unit Economics | 🟡 Pending | LTV:CAC >3:1 | Premium conv. 15%, CAC $50 via patient communities |
| Operational Scalability | 🟡 Pending | Automated trial sync | PWA scales globally; FHIR adapters ready |
| Team & Capital | 🟡 Pending | +1 FTE intl.; 12mo runway | $500K seed covers; hire local advisors |
2. Geographic Expansion Strategy
Market Prioritization
| Market | TAM (Patient Recruitment) | Competition | Entry Difficulty | Priority |
|---|---|---|---|---|
| USA (Core) | $1.2B | Medium | Low | Current |
| Canada/UK/Australia | $300M | Low | Low | 1st |
| EU (DE/FR/NL) | $500M | Medium | Medium | 2nd |
| India/LATAM | $200M | Low | High | 3rd |
Selection Criteria (Weighted Score)
- Market Size (25%): Recruitment spend (Statista 2023)
- Language/Regs (20%): English + similar privacy laws
- Competition (15%): Few patient-facing tools
- Entry Barriers (15%): Trial registries (e.g., EU-CTR)
- Strategic Fit (15%): Chronic disease prevalence
- Ease (10%): PWA + Stripe global
Phase 1: English Markets (M7-12)
Canada/UK/AU: Adapt to local registries (e.g., ISRCTN). Low localization. Invest $10K marketing. Exp. Rev: 20% total.
Phase 2: EU Localized (M13-18)
DE/FR: GDPR compliance, translate medical UI. Invest $40K. Exp. Rev: 15% total.
3. Localization Requirements
Product Localization
| Element | Phase 1 | Phase 2 | Effort |
|---|---|---|---|
| UI/Eligibility Translation | Not needed | Required | High |
| AI Patient Briefs | Minimal | Required | High |
| Date/Currency/Logistics | Easy | Easy | Low |
Operational Localization
- Payments: Stripe (global)
- Compliance: GDPR add-on ($5K)
- Support: Multilingual chat (Intercom)
- Trial Data: Integrate local APIs
Cost Estimates
| Market | Translation | Legal | Payments/Mktg | Total |
|---|---|---|---|---|
| Canada/UK/AU | $2K | $2K | $6K | $10K |
| Germany/France | $15K | $10K | $15K | $40K |
4. Market Expansion (New Segments)
Current: Individual patients/caregivers (chronic/rare diseases).
| Segment | TAM | Fit | Effort | Priority |
|---|---|---|---|---|
| Patient Advocacy Groups | $150M | High | Low | 1st |
| Hospitals/Patient Services | $400M | High | Medium | 1st |
| Pharma/CRO Leads | $800M | Medium | High | 2nd |
#1: Advocacy Groups (M6-9)
Bulk access for members. Changes: Group dashboards. GTM: Partnerships (e.g., Cancer.org). Pricing: $499/mo/group. Rev: $15K/mo.
#2: Hospitals (M10-12)
White-label for oncology depts. Changes: SSO, custom branding. GTM: Salesforce outreach. Pricing: $2K/mo. Rev: $50K/mo.
5. Business Model Expansion
White-Label Licensing High Viability
Hospitals/pharma. Rev: $5K/mo + lead fees. Timeline: M9. Pros: Scalable B2B.
API Model Medium
Integrate matching into EHRs. Usage pricing ($0.50/match). Timeline: M12+.
Franchise Low
Not suitable; digital-first product.
6. Expansion Roadmap & Projections
12-Month Plan
- PMF validation
- Playbook docs
- CA/UK/AU launch
- Group features
- EU pilot
- Hospital SSO
- API beta
| Timeframe | US | Phase 1 Geo | EU | New Segments | Total MRR |
|---|---|---|---|---|---|
| M6 | 80% | 15% | 0% | 5% | $15K |
| M12 | 55% | 20% | 10% | 15% | $60K |
| M18 | 45% | 20% | 15% | 20% | $180K |
7. Expansion Risks & Mitigations
#1 Premature Expansion 🔴 High
Mit: PMF gates. Pause if US retention drops.
#2 Regulatory (GDPR/HIPAA Intl) 🟡 Medium
Mit: Pre-entry legal audit ($10K), pilot compliant versions.
#3 Data/Translation Accuracy 🟡 Medium
Mit: Local clinicians review, A/B test briefs.
#4 Resource Dilution 🟡 Medium
Mit: Outsource localization, dedicate 20% team.
8. Expansion Success Metrics
| Metric | Definition | Target (M12) |
|---|---|---|
| Non-US Revenue | % of total MRR | 35% |
| New Market Payback | ROI time | <6 mo |
| Intl Retention | D30 in new markets | >35% |
| Segment Rev | New segments % | 20% |
| Checkpoint | Metric | Pass | Fail Action |
|---|---|---|---|
| Pre-Expand | US Retention | >40% | Delay |
| Phase 1 (M9) | Phase 1 Users | 500+ | Adjust GTM |
| Phase 2 (M12) | EU Rev | 10% total | Pivot/Exit |
Next Step: Secure US PMF, then pilot Canada beta in M7.